Trial Profile
A single-center retrospective study assessing the efficacy and safety of JAK inhibitors (JAKi) in Juvenile Dermatomyositis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Ruxolitinib (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- 18 Feb 2021 New trial record
- 12 Feb 2021 Results published in the Rheumatology